ClinicalTrials.gg
CompletedNCT04211545Updated May 8, 2020

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

A Phase 1 interventional study of Rabeprazole and CC-92480 in Healthy Volunteer, sponsored by Celgene. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-08.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, open-label, randomized, four-period, crossover study in healthy females of nonchildbearing potential and male subjects - to be conducted at a single center in the United States.

The study will consist of a screening phase, a baseline phase, four treatment periods, and a follow-up phone call. The 4 treatment periods are divided into two pairs (Period 1 and 2 and Period 3 and 4), potentially separated by an intermission during which subjects will be discharged from the research unit: Periods 1 and 2 support relative bioavailability (RBA) estimation, while Periods 3 and 4 support estimation of PPI effects.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Subjects
  • CC-92480
  • Pharmacokinetics
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted after Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study (partial):

  1. Must understand and voluntarily sign a written form (ICF) prior to any study-related assessments/procedures being performed.
  2. Must be able to communicate with the Investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules.
  3. Healthy adult male or female of any race, between 18 to 55 years of age (inclusive) at the time of signing the ICF, and in good health as determined by the screening history and PE.
  4. For males:

    1. Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of while participating in the study, during dose interruptions and for at least 3 months following product discontinuation, even if he has undergone a successful vasectomy.
    2. Agree to use barrier not made of natural (animal) membrane (eg, latex or polyurethane condoms are acceptable) when engaging in sexual activity with a female of childbearing potential (FCBP) 1 while on study medication, and for at 3 months after the last dose of study medication.
  5. Must have a between 18 and 33 kg/m2 (inclusive) at the time of signing the ICF.
  6. Clinical laboratory test results must be within the respective reference ranges; or if not, the results be clinically insignificant according to the Investigator's medical judgement.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. History of any and relevant neurological, GI, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders as determined by the Investigator.
  2. Exposure to an drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever is longer).
  3. Use of tobacco - or nicotine-containing products within 3 months prior to Day -1 (Period 1 for Part 2).
  4. Vaccination within 30 days of first dose administration or plans to receive vaccination within 30 days after dosing.
  5. Subjects with active hepatitis and
  6. Use of any nonprescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of the first dose administration.
  7. Use of inducers and inhibitors (including St. John's Wort) within 30 days of the first dose administration.
  8. Any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism and excretion (ADME), eg, bariatric procedure. Appendectomy and cholecystectomy are acceptable. Prior procedures of unclear ADME significance should be reviewed with the Sponsor's Medical Monitor.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Administration of CC-92480 and Rabeprazole

    Test Formulation CC-92480 and Reference Formulation will be administered orally at 1.6 mg. Rabeprazole will be administered orally at 40 mg.

    Drug: Rabeprazole · Drug: CC-92480

Interventions

  • DrugRabeprazole

    Rabeprazole

  • CC-92480

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics - AUC0-∞ (Reference Formulation)

    Area under the plasma concentration-time curve from time zero to infinity

    Time frame: Up to 5 days

  2. Pharmacokinetics - AUC0-∞ (Test Formulation)

    Area under the plasma concentration-time curve from time zero to the last observable concentration at time t

    Time frame: Up to 5 days

Secondary outcomes

  1. Pharmacokinetics -Cmax (Reference Formulation)

    Maximum plasma concentration

    Time frame: Day 1

  2. Pharmacokinetics - Cmax (Test Formulation)

    Maximum plasma concentration

    Time frame: Day 1

  3. Pharmacokinetics - AUC0-t (Reference Formulation)

    Area under the plasma concentration-time curve from time zero to the last observable concentration at time t

    Time frame: Up to 5 days

  4. Pharmacokinetics - AUC0-t (Test Formulation)

    Area under the plasma concentration-time curve from time zero to the last observable concentration at time t

    Time frame: Up to 5 days

  5. Pharmacokinetics -Tmax (Reference Formulation)

    Time to peak (maximum) plasma concentration

    Time frame: Day 1

  6. Pharmacokinetics -Tmax (Test Formulation)

    Time to peak (maximum)plasma concentration

    Time frame: Day 1

  7. Pharmacokinetics - CL/F (Reference Formulation)

    Apparent total plasma clearance

    Time frame: Up to 5 days

  8. Pharmacokinetics - CL/F (Test Formulation)

    Apparent total plasma clearance

    Time frame: Up to 5 days

  9. Pharmacokinetics - Vz/F (Reference Formulation)

    Apparent volume of distribution

    Time frame: Up to 5 days

  10. Pharmacokinetics - Vz/F (Test Formulation)

    Apparent volume of distribution

    Time frame: Up to 5 days

  11. Pharmacokinetics - t1/2 (Reference Formulation)

    Terminal elimination half-life

    Time frame: Up to 5 days

  12. Pharmacokinetics - t1/2 (Test Formulation)

    Terminal elimination half-life

    Time frame: Up to 5 days

  13. Adverse Events (AEs)

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values (as specified by the criteria in Section 10.3), regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.

    Time frame: From enrollment until at least 28 days after completion of study treatment

07

Study locations

1 site
  • PPD Phase 1 Clinic
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.celgene.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Dec 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2019
First posted
Dec 26, 2019
StartActual
Oct 21, 2019
Primary completionActual
Dec 26, 2019
CompletionActual
Dec 26, 2019
Last update
May 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04211545
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Dec 26, 2019
Start date
Oct 21, 2019
Primary completion
Dec 26, 2019
Completion
Dec 26, 2019
Last update
May 8, 2020

Study contacts

Leon Carayannopoulos, MD
study director · Celgene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezigdomide

Start the discussion